TCF1 links GIPR signaling to the control of beta cell function and survival

Nature Medicine

Volumn 22, Issue 1, 2016, Pages 84-90

  Campbell, Jonathan E ^a,b   Ussher, John R ^a,b   Mulvihill, Erin E ^a   Kolic, Jelena ^b,c   Baggio, Laurie L ^a   Cao, Xiemen ^a   Liu, Yu ^a   Lamont, Benjamin J ^a,b   Morii, Tsukasa ^a,b   Streutker, Catherine J ^d   Tamarina, Natalia ^e   Philipson, Louis H ^e   Wrana, Jeffrey L ^a   MacDonald, Patrick E ^b,c   Drucker, Daniel J ^a,f  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e NONE   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INCRETIN; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PROTEIN BCL 2; SITAGLIPTIN; TRANSCRIPTION FACTOR 7; X LINKED INHIBITOR OF APOPTOSIS; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HNF1A PROTEIN, MOUSE; HORMONE RECEPTOR; MESSENGER RNA; TCF7 PROTEIN, HUMAN;

ADULT; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CASE REPORT; CELL DAMAGE; CELL FUNCTION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; GENE SILENCING; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID DIET; LOW DRUG DOSE; MALE; MIDDLE AGED; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHITE ADIPOSE TISSUE; WILD TYPE; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; GENE INACTIVATION; GENETICS; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; PANCREAS ISLET; REAL TIME POLYMERASE CHAIN REACTION; SECRETION (PROCESS); SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GENE KNOCKOUT TECHNIQUES; GLUCOSE TOLERANCE TEST; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GASTROINTESTINAL HORMONE; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; T CELL TRANSCRIPTION FACTOR 1;

EID: 84954396103     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3997     Document Type: Article

References (45)

1. Campbell, J.E., Drucker, D.J. Pharmacology physiology and mechanisms of incretin hormone action. Cell Metab. 17, 819-837 (2013).
2. Saxena, R. et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat. Genet. 42, 142-148 (2010).
3. Speliotes, E.K. et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 42, 937-948 (2010).
4. Miyawaki, K. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738-742 (2002).
5. Mulvihill, E.E., Drucker, D.J. Pharmacology, physiology and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35, 992-1019 (2014).
6. Finan, B. et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys and humans. Sci. Transl. Med. 5, 209ra151 (2013).
7. Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27-36 (2015).
8. Shu, L. et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP-and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet. 18, 2388-2399 (2009).
9. Wessel, J. et al. Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat. Commun. 6, 5897 (2015).
10. Miyawaki, K. et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. USA 96, 14843-14847 (1999).
11. Meier, J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728-742 (2012).
12. Nauck, M.A. et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91, 301-307 (1993).
13. Højberg, P.V. et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52, 199-207 (2009).
14. Brouwers, B. et al. Impaired islet function in commonly used transgenic mouse lines due to human growth hormone minigene expression. Cell Metab. 20, 979-990 (2014).
15. Oropeza, D. et al. Phenotypic characterization of MIP-CreERT1Lphi mice with transgene-driven islet expression of human growth hormone. Diabetes 64, 3798-3807 (2015).
16. Mehran, A.E. et al. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab. 16, 723-737 (2012).
17. Chen, S., Okahara, F., Osaki, N., Shimotoyodome, A. Increased GIP signaling induces adipose inflammation via a HIF-1alpha-dependent pathway and impairs insulin sensitivity in mice. Am. J. Physiol. Endocrinol. Metab. 308, E414-E425 (2015).
18. Lamont, B.J., Drucker, D.J. Differential anti-diabetic efficacy of incretin agonists vs. DPP-4 inhibition in high fat fed mice. Diabetes 57, 190-198 (2008).
19. Ali, S., Lamont, B.J., Charron, M.J., Drucker, D.J. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J. Clin. Invest. 121, 1917-1929 (2011).
20. Pamir, N. et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am. J. Physiol. Endocrinol. Metab. 284, E931-E939 (2003).
21. Pederson, R.A. et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor/mice. Diabetes 47, 1046-1052 (1998).
22. Mayo, K.E. et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55, 167-194 (2003).
23. Kim, S.J. et al. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB) signaling, inactivation of the Forkhead transcription factor Foxo1 and downregulation of bax expression. J. Biol. Chem. 280, 22297-22307 (2005).
24. Maida, A., Hansotia, T., Longuet, C., Seino, Y., Drucker, D.J. Differential importance of GIP versus GLP-1 receptor signaling for beta cell survival in mice. Gastroenterology 137, 2146-2157 (2009).
25. Shu, L. et al. Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 57, 645-653 (2008).
26. Yusta, B. et al. GLP-1 receptor activation improves-cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 4, 391-406 (2006).
27. Li, Y. et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278, 471-478 (2003).
28. Van de Wetering, M., Castrop, J., Korinek, V., Clevers, H. Extensive alternative splicing and dual promoter usage generate Tcf-1 protein isoforms with differential transcription control properties. Mol. Cell. Biol. 16, 745-752 (1996).
29. Ioannidis, V., Beermann, F., Clevers, H., Held, W. The beta-catenin-TCF-1 pathway ensures CD4+CD8+ thymocyte survival. Nat. Immunol. 2, 691-697 (2001).
30. Vlotides, G., Eigler, T., Melmed, S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr. Rev. 28, 165-186 (2007).
31. Lyssenko, V. et al. Pleiotropic effects of GIP on islet function involves osteopontin. Diabetes 60, 2424-2433 (2011).
32. Grant, S.F. et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38, 320-323 (2006).
33. Florez, J.C. et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355, 241-250 (2006).
34. Boj, S.F. et al. Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 151, 1595-1607 (2012).
35. Kaur, K. et al. Elevated hepatic miR-22-3p expression impairs gluconeogenesis by silencing the Wnt-responsive transcription factor, Tcf7. Diabetes 64, 3659-3669 (2015).
36. Columbus, J. et al. Insulin treatment and high-fat diet feeding reduces the expression of three Tcf genes in rodent pancreas. J. Endocrinol. 207, 77-86 (2010).
37. Noble, J.A. et al. A polymorphism in the TCF7 gene, C883A, is associated with type 1 diabetes. Diabetes 52, 1579-1582 (2003).
38. Erlich, H.A., Valdes, A.M., Julier, C., Mirel, D., Noble, J.A. Evidence for association of the TCF7 locus with type I diabetes. Genes Immun. 10 (suppl. 1), S54-S59 (2009).
39. Wang, Z., Moro, E., Kovacs, K., Yu, R., Melmed, S. Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc. Natl. Acad. Sci. USA 100, 3428-3432 (2003).
40. Chesnokova, V. et al. Diminished pancreatic beta-cell mass in securin-null mice is caused by beta-cell apoptosis and senescence. Endocrinology 150, 10 (suppl. 1) 2603-2610 (2009).
41. Wicksteed, B. et al. Conditional gene targeting in mouse pancreatic ss-cells: analysis of ectopic Cre transgene expression in the brain. Diabetes 59, 3090-3098 (2010).
42. Scrocchi, L.A. et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat. Med. 2, 1254-1258 (1996).
43. Verbeek, S. et al. An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature 374, 70-74 (1995).
44. Patterson, J.T. et al. A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem. Biol. 6, 135-145 (2011).
45. Lamont, B.J. et al. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J. Clin. Invest. 122, 388-402 (2012).